Sumit K. Subudhi

11.3k total citations · 8 hit papers
108 papers, 7.3k citations indexed

About

Sumit K. Subudhi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Sumit K. Subudhi has authored 108 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 54 papers in Pulmonary and Respiratory Medicine and 42 papers in Immunology. Recurrent topics in Sumit K. Subudhi's work include Cancer Immunotherapy and Biomarkers (58 papers), Prostate Cancer Treatment and Research (48 papers) and Immunotherapy and Immune Responses (30 papers). Sumit K. Subudhi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (58 papers), Prostate Cancer Treatment and Research (48 papers) and Immunotherapy and Immune Responses (30 papers). Sumit K. Subudhi collaborates with scholars based in United States, United Kingdom and Spain. Sumit K. Subudhi's co-authors include Padmanee Sharma, James P. Allison, Jianjun Gao, Sangeeta Goswami, Yang‐Xin Fu, Bilal A. Siddiqui, Swetha Anandhan, Ana M. Aparicio, Eleni Efstathiou and Jorge Blando and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Sumit K. Subudhi

99 papers receiving 7.2k citations

Hit Papers

Glucocorticoid Receptor Confers Resistance to An... 2003 2026 2010 2018 2013 2023 2014 2003 2021 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
    2013 703 citations Sumit K. Subudhi, Eleni Efstathiou et al. profile →
  2. Immune checkpoint therapy—current perspectives and future directions
    2023 579 citations Padmanee Sharma, Bilal A. Siddiqui et al. profile →
  3. Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
    2014 564 citations Sumit K. Subudhi, James P. Allison et al. Science Translational Medicine profile →
  4. Cutting Edge: CD28 Controls Peripheral Homeostasis of CD4+CD25+ Regulatory T Cells
    2003 546 citations Qizhi Tang, Kammi Henriksen et al. The Journal of Immunology profile →
  5. The Next Decade of Immune Checkpoint Therapy
    2021 480 citations Padmanee Sharma, Bilal A. Siddiqui et al. profile →
  6. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
    2017 455 citations Sumit K. Subudhi, Luis M. Vence et al. profile →
  7. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
    2018 266 citations Anu Sharma, Sumit K. Subudhi et al. Clinical Cancer Research profile →
  8. Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
    2018 182 citations Ana M. Aparicio, Sumit K. Subudhi et al. profile →

Peers

Sumit K. Subudhi
Philip M. Arlen United States
Leah Haworth United States
Kristen E. Pauken United States
Gregory A. Daniels United States
Robert B. Sims United States
Yoshiko Iwai Japan
Miguel F. Sanmamed Spain
Douglas G. McNeel United States
Marcus O. Butler Canada
Ravindra Uppaluri United States
Philip M. Arlen United States
Sumit K. Subudhi
Citations per year, relative to Sumit K. Subudhi Sumit K. Subudhi (= 1×) peers Philip M. Arlen

Countries citing papers authored by Sumit K. Subudhi

Since Specialization
Citations

This map shows the geographic impact of Sumit K. Subudhi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sumit K. Subudhi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sumit K. Subudhi more than expected).

Fields of papers citing papers by Sumit K. Subudhi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sumit K. Subudhi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sumit K. Subudhi. The network helps show where Sumit K. Subudhi may publish in the future.

Co-authorship network of co-authors of Sumit K. Subudhi

This figure shows the co-authorship network connecting the top 25 collaborators of Sumit K. Subudhi. A scholar is included among the top collaborators of Sumit K. Subudhi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sumit K. Subudhi. Sumit K. Subudhi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Subudhi, Sumit K., Wim Vos, Massimo Andreatta, et al.. (2025). Perspectives on the role of “-Omics” in predicting response to immunotherapy. European Journal of Cancer. 220. 115393–115393. 2 indexed citations
2.
3.
Ali, Abdelrahman, Lu Yang, Shaden Khalaf, et al.. (2024). Use of positron emission tomography for the diagnosis of immune-checkpoint inhibitor| myocarditis. Journal of Nuclear Cardiology. 39. 101909–101909.
4.
Siddiqui, Bilal A., Nicolas L. Palaskas, Sreyashi Basu, et al.. (2024). Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis. Cancer Immunology Research. 12(8). 964–987. 7 indexed citations
5.
Tidwell, Rebecca S., Yao Yu, Amado J. Zurita, et al.. (2024). Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocrine Related Cancer. 31(12).
6.
Subudhi, Sumit K., Chih‐Yi Liao, Shun Zhang, et al.. (2024). The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(4_suppl). 133–133.
7.
Antonarakis, Emmanuel S., Sumit K. Subudhi, Christopher Pieczonka, et al.. (2023). Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. Clinical Cancer Research. 29(13). 2426–2434. 10 indexed citations
8.
Subudhi, Sumit K., Gerald S. Falchook, Mohamad A. Salkeni, et al.. (2023). 759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors. SHILAP Revista de lepidopterología. A855–A855.
9.
Tidwell, Rebecca S., Miao Zhang, Keyi Zhu, et al.. (2023). Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments. Cancers. 15(24). 5843–5843. 2 indexed citations
10.
Drake, Charles G., Russell K. Pachynski, Sumit K. Subudhi, et al.. (2021). Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 25(2). 219–228. 28 indexed citations
11.
Davis, John W., Amado J. Zurita, Xuemei Wang, et al.. (2021). Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. European Journal of Cancer. 157. 259–267. 12 indexed citations
12.
Subudhi, Sumit K., Luis M. Vence, Hao Zhao, et al.. (2020). Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Science Translational Medicine. 12(537). 116 indexed citations
13.
Kim, Sang T., William A. Murphy, Ana M. Aparicio, & Sumit K. Subudhi. (2020). RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer. SHILAP Revista de lepidopterología. 3(3). 128–132. 2 indexed citations
14.
Vence, Luis M., Samantha Bucktrout, Irina Fernandez Curbelo, et al.. (2019). Characterization and Comparison of GITR Expression in Solid Tumors. Clinical Cancer Research. 25(21). 6501–6510. 38 indexed citations
15.
Sharma, Anu, Sumit K. Subudhi, Jorge Blando, et al.. (2018). Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clinical Cancer Research. 25(4). 1233–1238. 266 indexed citations breakdown →
16.
Anders, Robert A., Sumit K. Subudhi, Jing Wang, Klaus Pfeffer, & Yang‐Xin Fu. (2005). Contribution of the Lymphotoxin β Receptor to Liver Regeneration. The Journal of Immunology. 175(2). 1295–1300. 59 indexed citations
17.
Tang, Qizhi, Kammi Henriksen, Elisa K. Boden, et al.. (2003). Cutting Edge: CD28 Controls Peripheral Homeostasis of CD4+CD25+ Regulatory T Cells. The Journal of Immunology. 171(7). 3348–3352. 546 indexed citations breakdown →
18.
Tang, Qizhi, et al.. (2002). The Src Family Kinase Fyn Mediates Signals Induced by TCR Antagonists. The Journal of Immunology. 168(9). 4480–4487. 23 indexed citations
19.
Sun, Yonglian, et al.. (2002). Administration of Agonistic Anti-4-1BB Monoclonal Antibody Leads to the Amelioration of Experimental Autoimmune Encephalomyelitis. The Journal of Immunology. 168(3). 1457–1465. 163 indexed citations
20.
Subudhi, Sumit K., Russell P. Rother, Susan J. Faas, et al.. (2001). Inducible Costimulator Regulates Th2-Mediated Inflammation, but Not Th2 Differentiation, in a Model of Allergic Airway Disease. The Journal of Immunology. 167(4). 1996–2003. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Philip M. Arlen Breakdown of academic impact, for papers by Leah Haworth Breakdown of academic impact, for papers by Kristen E. Pauken Breakdown of academic impact, for papers by Gregory A. Daniels Breakdown of academic impact, for papers by Robert B. Sims Breakdown of academic impact, for papers by Yoshiko Iwai Breakdown of academic impact, for papers by Miguel F. Sanmamed Breakdown of academic impact, for papers by Douglas G. McNeel Breakdown of academic impact, for papers by Marcus O. Butler Breakdown of academic impact, for papers by Ravindra Uppaluri
Rankless by CCL
2026